Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) Equity Average (2016 - 2025)

CorMedix's Equity Average history spans 12 years, with the latest figure at $389.7 million for Q4 2025.

  • For Q4 2025, Equity Average rose 443.66% year-over-year to $389.7 million; the TTM value through Dec 2025 reached $389.7 million, up 443.66%, while the annual FY2025 figure was $245.0 million, N/A changed from the prior year.
  • Equity Average for Q4 2025 was $389.7 million at CorMedix, up from $297.4 million in the prior quarter.
  • Across five years, Equity Average topped out at $389.7 million in Q4 2025 and bottomed at $51.5 million in Q2 2023.
  • The 5-year median for Equity Average is $66.1 million (2021), against an average of $99.5 million.
  • The largest annual shift saw Equity Average crashed 68.81% in 2021 before it soared 467.0% in 2025.
  • A 5-year view of Equity Average shows it stood at $66.1 million in 2021, then dropped by 15.72% to $55.7 million in 2022, then grew by 18.75% to $66.1 million in 2023, then grew by 8.41% to $71.7 million in 2024, then soared by 443.66% to $389.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Equity Average are $389.7 million (Q4 2025), $297.4 million (Q3 2025), and $167.8 million (Q2 2025).